Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Takeda Terminates Fasiglifam Development | Contract Pharma

What are you searching for?

Sign in
Breaking News

Takeda Terminates Fasiglifam Development

Diabetes drug draws concerns about liver safety

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Takeda Pharmaceutical Co. has decided to terminate development of fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. The company has worked with three independent panels regarding safety oversight, including the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program.
 
Following a review of the data emerging from all the clinical trials and in consultation with these panels, the company has decided that the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks, and has decided to voluntarily terminate development activities for fasiglifam.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics